Recently, BeBetter Med Inc. successfully completed the Phase I clinical trial of BEBT-503in Australia. BEBT-503 is a pan-PPAR agonist developed by BebetterMed, boasting exclusive global intellectual property rights. The trial was a randomized, double-blind, placebo-controlled clinical study conducted in healthy volunteers to assess the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of BEBT-503. The trial results demonstrated good safety and tolerability of BEBT-503 across all dose groups, with pharmacokinetic characteristics aligning with expectations. Only mild adverse events occurred during the study, and the incidences were similar among participants receiving the placebo and BEBT-503, with no moderate or severe adverse events reported. Currently, BeBetter Med is initiating Phase I bridging trial in healthy volunteers and Phase II clinical trial for the treatment of diabetes with non-alcoholic fatty liver disease (NAFLD) under randomized, double-blind, placebo-controlled conditions in China.

 This month, Dr. Changgeng Qian, Chairman of BeBetter Med, and Mr. Yan Xiong, Vice Chairman, visited the clinical research collaboration partners Nucleus Network, 360 Biolabs, and George Clinical Centre in Australia,. The purpose of the visits was to strengthen business communication with the partners, summarize the collaborative experience from Phase I clinical trial of BEBT-503, and explore efficient modes of cooperation for conducting new clinical trials in Australia and international multicenter clinical research projects.

 Dr. Changgeng Qian and Mr. Yan Xiong held in-depth discussions and exchanges with Dr. Jason Lickliter, Chief Medical Officer of Nucleus Network, Mr. Jeff Wong, Senior Director of BD, and their team in Melbourne. Nucleus Network is currently the largest Phase I clinical research organization in Australia. Both parties highly praised the collaboration on the Phase I clinical trial of BEBT-503. Dr. Qian expressed his deep appreciation for the specialized capabilities of the Nucleus Network team and their contribution. Dr. Lickliter provided a detailed overview of the advantages of conducting clinical trials in Australia and expanding global international collaborations, which he believes will positively contribute to the acceleration of the development of the innovative pharmaceutical industry in China. Both parties are enthusiastic about future collaborations.

 Following this, Dr. Changgeng Qian and Mr. Yan Xiong visited 360 Biolabs, an Australian specialty laboratory focused on the testing of clinical trial sample analysis. Ms. Sharon Sim, Senior Business Development of 360 Biolabs, expressed a strong desire to enhance cooperation between the two parties and believed that their collaboration would further improve the quality and efficiency of clinical research.

 Mr. Yan Xiong expressed that BeBetter Med is very pleased to establish a close partnership with 360 Biolabs and hopes to meet the future needs of clinical research sample testing through strengthened collaboration with 360 Biolabs.

 About BEBT-503:

 BEBT-503 is a highly active pan-PPAR agonist primarily used for the treatment of diabetes with non-alcoholic fatty liver disease. Preclinical studies have shown that BEBT-503 can reduce baseline blood glucose and improve glucose tolerance in the CDAHFD mouse model of diabetes with non-alcoholic steatohepatitis, with the significant advantage of not increasing mouse body weight during treatment. In September 2022, the company initiated the Phase I clinical trial of BEBT-503 in Australia. In October 2022 and February 2023, BEBT-503 received approvals for Phase I and Phase II clinical trials in China for type 2 diabetes with non-alcoholic fatty liver disease (including non-alcoholic fatty liver and non-alcoholic steatohepatitis) and primary biliary cholangitis, respectively.

 About BeBetter Med:

 BeBetter Med Inc. is a biopharmaceutical company focused on the research and development of breakthrough medications in vital therapeutic fields such as oncology, autoimmune diseases, and metabolic disorders. Established in 2012 in Guangzhou by Professor Changgeng Qian alongside a cadre of global returnees, BeBetter Med utilizes its proprietary technology platform to formulate groundbreaking pharmaceutical solutions that balance clinical effectiveness with practical utility. Adhering to the ethos of "Committed to Innovation, Striving for Excellence," the company is unwavering in its commitment to independent research and development of globally patented, safe, and effective medications.